BofA raised the firm’s price target on Haemonetics (HAE) to $90 from $75 and keeps a Neutral rating on the shares. The firm’s higher target reflects last quarter’s plasma market turn and the reset of Vacasde guidance, the analyst tells investors.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HAE:
- Haemonetics price target raised to $75 from $65 at Mizuho
- Haemonetics Reports Positive Earnings Call with Growth Highlights
- Haemonetics upgraded to Neutral from Underperform at BofA
- Haemonetics price target raised to $90 from $86 at Barrington
- Haemonetics price target raised to $82 from $65 at Baird